**Supplementary Table S2:** Prevalence of hr-HPV types among all 85 CIN2+† cases, stratified by race and ethnicity

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **hr-HPV Type** | **Hispanic****n=32** | **Non-Hispanic Black****n=13** | **Non-Hispanic White****n=34** | **Other****n=6** |
| **Self** | **Provider** | **Self** | **Provider** | **Self** | **Provider** | **Self** | **Provider** |
|  | **n (%)** | **n (%)** | **n (%)** | **n (%)** | **n (%)** | **n (%)** | **n (%)** | **n (%)** |
| **All hr-HPV\*** | 29 (91%) | 31 (97%) | 12 (92%) | 12 (92%) | 32 (94%) | 31 (91%) | 6 (100%) | 6 (100%) |
| **16** | 13 (41%) | 13 (41%) | 5 (38%) | 2 (15%) | 18 (53%) | 16 (47%) | 3 (50%) | 3 (50%) |
| **18** | 2 (6%) | 3 (9%) | 3 (23%) | 2 (15%) | 2 (6%) | 1 (3%) | 0 (0%) | 0 (0%) |
| **31** | 3 (9%) | 3 (9%) | 2 (15%) | 2 (15%) | 2 (6%) | 1 (3%) | 2 (33%) | 2 (33%) |
| **45** | 2 (6%) | 3 (9%) | 2 (15%) | 0 (0%) | 2 (6%) | 2 (6%) | 0 (0%) | 0 (0%) |
| **33/58** | 5 (16%) | 5 (16%) | 2 (15%) | 1 (8%) | 3 (9%) | 3 (9%) | 0 (0%) | 0 (0%) |
| **35/39/68** | 2 (6%) | 2 (6%) | 3 (23%) | 4 (31%) | 8 (24%) | 8 (24%) | 0 (0%) | 0 (0%) |
| **51** | 1 (3%) | 1 (3%) | 0 (0%) | 0 (0%) | 6 (18%) | 6 (18%) | 1 (17%) | 1 (17%) |
| **52** | 5 (16%) | 5 (16%) | 4 (31%) | 4 (31%) | 3 (9%) | 3 (9%) | 1 (17%) | 1 (17%) |
| **56/59/66** | 2 (6%) | 2 (6%) | 4 (31%) | 4 (31%) | 11 (32%) | 11 (32%) | 0 (0%) | 0 (0%) |

\*hr-HPV: Any of the 14 high-risk HPV types detected by the Onclarity assay

†CIN2+: Cervical intraepithelial neoplasia grade 2 or highe